World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: JPRN
Last refreshed on: 17 October 2023
Main ID:  JPRN-jRCTs041190126
Date of registration: 10/03/2020
Prospective Registration: Yes
Primary sponsor: Katsuno Masahisa
Public title: Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease
Scientific title: Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body disease - NaT-PROBEi
Date of first enrolment: 22/02/2021
Target sample size: 30
Recruitment status: Not Recruiting
URL:  https://jrct.niph.go.jp/latest-detail/jRCTs041190126
Study type:  Interventional
Study design:  randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose  
Phase:  2
Countries of recruitment
Contacts
Name: Masahisa    Katsuno
Address:  65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan 466-8550 Aichi Japan
Telephone: +81-52-744-2391
Email: ka2no@med.nagoya-u.ac.jp
Affiliation:  Nagoya University Graduate School of Medicine
Name: Keita    Hiraga
Address:  65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan 466-8550 Aichi Japan
Telephone: +81-52-744-2391
Email: hiraga@med.nagoya-u.ac.jp
Affiliation:  Nagoya University Graduate School of Medicine
Key inclusion & exclusion criteria
Inclusion criteria: 1. Subjects whose age is between 50 and 80 years old
2. Subjects who have two or more prodromal symptoms:
SCOPA-AUT: 10 or more
RBDSQ: 5 or more, or REM sleep without atonia (RWA) finding of polysomnography
OSIT-J: 7 or less, or SAOQ: 90% or less
3. Subjects who fulfill one of the following criteria:
In cardiac MIBG scintigraphy, H/M ratio is less than 2.2 in early-phase and/or delayed-phase
In DaT SPECT, SBR is lower than the limit of z-score for each age using DaTVIEW analysis (left and/or right side), or DAT deficiency in the striatum
4. Subjects who can make an outpatient visit regularly
5. Subjects who agree to participate in this study

Exclusion criteria: 1. Subjects who received zonisamide within 4 weeks from screening
2. Subjects with hypersensitivity to TRERIEF
3. Subjects who take medicine which affect blood concentration of zonisamide: strong inhibitors of CYP3A
4. Subjects with severe heart disease (myocardial infarction, angina, etc)
5. Subjects with severe hepatic or renal dysfunction
6. Subjects diagnosed with Parkinson's disease or dementia with Lewy body
7. Subjects with mental or neurological disorders other than depression
8. Subjects with other severe complications
9. Female subjects who are pregnant or breast-feeding, those with positive urine hCG pregnancy test
10. Subjcets who disagree with contraception during the study period
11. Subjects diagnosed with dementia or other neurological disorders using brain MRI at screening
12. Subjects who are inappropriate to participate in the study
13. Subjects who received other investigational drugs within 1 year
14. Subjects who participate in other clinical trials. Prospective study on early diagnosis of Parkinson's disease in medical checkup examinees with non-motor symptoms (NaT-PROBE) is excluded.


Age minimum: >= 50age old
Age maximum: < 80age old
Gender: Both
Health Condition(s) or Problem(s) studied
Lewy body disease (Parkinson's disease and dementia with Lewy bodies)
Intervention(s)
Arm zonisamide:
1.Two tablets of zonisamide 25mg after breakfast for 4 weeks
2.Four tablets of zonisamide 25mg after breakfast for 92 weeks
Arm placebo:
1.Two tablets of placebo after breakfast for 4 weeks
2.Four tablets of placebo after breakfast for 92 weeks
Primary Outcome(s)
Change of the average of SBR in the right and left sides in DaT SPECT from week 0
Secondary Outcome(s)
1. Change of the following measures from 0 week:
Change of SBR of each side in DaT SPECT
MDS-UPDRS
MoCA-J
Trail making test
Stroop test
Line orientation test
pareidolia test
H/M ratio on cardiac MIBG scintigraphy
OSIT-J
Schellong test
CVR-R on electrocardiogram
PASE
SCOPA-AUT-J
RBDSQ-J
PDQ-39
BDI-II
SAOQ
JESS
QUIP-Current-Short
2. Subjects who fulfill the diagnostic criteria for Parkinson's disease or dementia with Lewy bodies
Secondary ID(s)
Source(s) of Monetary Support
Sumitomo Pharma Co., Ltd.
Secondary Sponsor(s)
Japan Agency for Medical Research and Development
Ethics review
Status: Approval
Approval date: 18/02/2020
Contact:
ethics@med.nagoya-u.ac.jp
Nagoya University Clinical Research Review Board
+81-52-744-2479
ethics@med.nagoya-u.ac.jp
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey